- Home
- VSTM vs MAIA Comparison
VSTM vs MAIA Comparison
Compare VSTM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- MAIA
- Stock Information
- Founded
- VSTM 2010
- MAIA 2018
- Country
- VSTM United States
- MAIA United States
- Employees
- VSTM N/A
- MAIA N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- VSTM Health Care
- MAIA Health Care
- Exchange
- VSTM Nasdaq
- MAIA Nasdaq
- Market Cap
- VSTM 425.9M
- MAIA 46.7M
- IPO Year
- VSTM 2012
- MAIA 2022
- Fundamental
- Price
- VSTM $4.68
- MAIA $1.85
- Analyst Decision
- VSTM Strong Buy
- MAIA
- Analyst Count
- VSTM 9
- MAIA 0
- Target Price
- VSTM $12.63
- MAIA N/A
- AVG Volume (30 Days)
- VSTM 2.5M
- MAIA 543.2K
- Earning Date
- VSTM 08-07-2025
- MAIA 08-08-2025
- Dividend Yield
- VSTM N/A
- MAIA N/A
- EPS Growth
- VSTM N/A
- MAIA N/A
- EPS
- VSTM N/A
- MAIA N/A
- Revenue
- VSTM $10,000,000.00
- MAIA N/A
- Revenue This Year
- VSTM $129.06
- MAIA N/A
- Revenue Next Year
- VSTM $306.32
- MAIA N/A
- P/E Ratio
- VSTM N/A
- MAIA N/A
- Revenue Growth
- VSTM N/A
- MAIA N/A
- 52 Week Low
- VSTM $2.10
- MAIA $1.40
- 52 Week High
- VSTM $9.10
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- VSTM 40.17
- MAIA 53.36
- Support Level
- VSTM $4.01
- MAIA $1.82
- Resistance Level
- VSTM $5.06
- MAIA $2.03
- Average True Range (ATR)
- VSTM 0.34
- MAIA 0.12
- MACD
- VSTM 0.02
- MAIA 0.02
- Stochastic Oscillator
- VSTM 44.81
- MAIA 58.14
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.